DCTH - Earnings announcements

2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025 HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025 CHEMOSAT® revenue of $1.7 million, compared to $1.8 million in the first quarter of 2025 Gross margins of 85%, compared to 86% in t

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 7, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-800-717-1738 International: 1-646-307-1865 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1757946&tp_key=463dd4d428 A replay of the webinar will be available short

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT™ revenue of $19.3 million, compared to $10.0 million in the third quarter of 2024 CHEMOSAT® revenue of $1.3 million, compared to $1.2 million in the third quarter of 2024 Gross margins of 87%, compared to 85% in the third quarte

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November 4, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1735083&tp_key=a3bb91787b A replay of the webinar will be a

Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million HEPZATO KIT revenue of $19.2 million CHEMOSAT revenue of $1.3 million Gross margins expected to be 87% Net income of $0.8 million Positive adjusted EBITDA of $5.3 million Positive operating cashflow of approximately $4.8 mill

Conference Call October 20, 8:45am EST Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology at the 2025 European Society of Medical Oncology (ESMO) Annual Congress. CHOPIN Trial Design The investigator-initiated, prospective, randomized Phase 2 CHOPIN Trial was designed to compare the safety, tolerability, and efficacy of Delcath's CHEMOSAT® Hepatic Delivery Sy

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT™ revenue of $22.5 million, compared to $6.6 million in the second quarter of 2024 CHEMOSAT® revenue of $1.7 million, compared to $1.2 million in the second quarter of 2024 Gross margins of 86%, compared to 80% in the second q

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1723203&tp_key=fbe0333159 A replay of the webinar will be availab

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 6, 2025, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, March 6, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1706497&tp_key=9763647546 A replay of the webinar will

Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter and Recent Business Highlights Total third quarter revenues of $11.2 million, up 44% from the prior quarter, including $10.0 million from HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million from CHEMOSAT®; Activated four HEPZATO treatment centers in the U.S. during the third quarter and one more in October, bringing the total to twelve

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Friday, November 8, 2024 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691899&tp_key=9d94cb0736 A replay of the webinar will be availab

Company Reports $7.8 million in Quarterly Revenue Conference Call Today at 4:30pm Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the second quarter ended June 30, 2024. Recent Business Highlights Recognized second quarter 2024 revenues of $6.6 million from sales of HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million in CHEMOSAT sales; Activated three HEPZATO KIT treating centers in the US during the second quarter with an additional center in July for a total of eigh

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Monday, August 5, 2024 Time: 4:30 PM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1679582&tp_key=87da4fb106 A replay of the webinar will be available

Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y., May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the first quarter ended March 31, 2024. Recent Business HighlightsDuring and since the first quarter, Delcath: Recognized over $2.0 million of revenue from sales of HEPZATO KIT (melphalan/Hepatic Delivery System) and $1.1 million in CHEMOSAT sales through

QUEENSBURY, N.Y., May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.   Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, May 14, 2024Time: 8:30 AM Eastern Time Participant Numbers:Toll Free: 1-833-630-1960Inte

NEW YORK, March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 26, 2024, at 8:30 AM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023 and provide a business update.  Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, March 26, 2024Time: 8:30 AM Eastern TimeParticipa

HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic met

NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2Q23 earnings and issue its Form 10-Q the week of August 7, 2023. Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug application ("NDA") resubmission, Delcath expects to hold a conference call to review the quarter and the details of the FDA action.  Delcath currently expects the FDA to finish their review and take action on the application by the August 14, 2023 Prescription Drug User Fee Act ("PDUFA") date.  

NEW YORK, May 12, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023. Recent Business Highlights During and since the first quarter, Delcath: Received an acknowledgement of Class 2 NDA resubmission from the U.S. Food and Drug Administration (FDA) for Hepzato Kit® (melphalan hydrochloride for Injection/Hepatic Delivery S

NEW YORK, May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023.   Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Event Date: Friday, May 12, 2023Time: 8:30 AM Eastern TimeParticipant Numbers: Toll Free: 1-833-630-1960International: 1

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. Recent Business Highlights During and since the fourth quarter, Delcath Systems, Inc. (Delcath or the Company): Received an acceptance of the NDA resubmission from the U.S. Food and Drug Administration (FDA) for Hepzato Kit® (melphalan hydrochloride for injection/Hepatic Delive

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2022. Recent Business Highlights During and since the third quarter, Delcath: Confirmed the pending resubmission of the NDA for the Hepzato Kit® (melphalan hydrochloride for injection/Hepatic Delivery System) to the FDA by the end of the year,Attracted a growing number of sites to our Expanded Acces

NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2022.   Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November 8, 2022Time: 8:30 AM Eastern TimeParticipant Numbers: Toll Free: 1-844-836-8745I

NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2022. Recent Business Highlights During and since the second quarter, Delcath: Held a pre-NDA meeting with FDA and locked the phase 3 FOCUS Trial database for the purpose of resubmitting the NDA for the Hepzato Kit® (melphalan hydrochloride for injection/hepatic delivery system) in the third quarter of

NEW YORK, July 27, 2022 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2022.   Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Event Date: Monday, August 8, 2022Time: 8:30 AM Eastern TimeParticipant Numbers: Toll Free: 1-844-836-8745Internatio

NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022. Recent Business Highlights During and since the first quarter, Delcath: Held a pre-NDA meeting with FDA and announced plans to file an NDA in the third quarter of 2022,Announced the acceptance of a poster presentation updating results from the FOCUS Phase 3 Trial at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting,Resumed direct responsibility for sales, marketing, and dist

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 10, 2022, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2022. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, May 10, 2022Time: 8:30 AM Eastern TimeParticipant Numbers: Toll Free: 877-545-0523; Participant Access Code: 633971International: 973-528-0016 Participant Access Code: 633971Webcast: https://www.webcaster4.

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021. Recent Business Highlights During and since the fourth quarter, Delcath: Reported updated positive phase 3 FOCUS trial results for HEPZATO™ Kit (melphalan hydrochloride for injection/hepatic delivery system) for the treatment of patients with unresectable liver-dominant metastatic ocular melanoma, including initial survival data analysisConfirmed guidance for the mid-year Class 2 res

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: March 25, 2022Time: 8:30 AM Eastern TimeToll Free: 888-506-0062; Entry Code: 938572International: 973-528-0011; Entry Code: 938572 The call will also be available over the Internet and accessible at:

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021. Recent Business Highlights During and since the third quarter Delcath: Entered a debt facility with Avenue Venture Opportunities Fund, L.P. providing up to $20 million with an initial $15 million funded at closing,Submitted to and received approval from the FDA for an expanded access protocol for the use of HEPZATO™ Kit (melphalan hydrochloride for injection/hepatic delivery system) in the tr

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: November 9, 2021Time: 8:30 AM Eastern TimeToll Free: 888-506-0062; Entry Code: 676028International: 973-528-0011; Entry Code: 676028 The call will also be available over the Internet and accessible at: https://ww

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021. Recent Business Highlights During and since the second quarter the company: Had positive efficacy results presented from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma (mOM) at the American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation by the study's Le

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Date: August 10, 2021Time: 8:30 AM Eastern TimeToll Free: 877-545-0523; Entry Code: 148562International: 973-528-0016; Entry Code: 148562 The call will also be available over the Internet and accessible at: